article thumbnail

IV Robotics and the Latest USP Revisions

Omnicell

The latest revisions, which take effect November 1, 2023, exempt some robotic devices from surface sampling after every batch of Category 3 compounded sterile products (CSPs) and instead allow users of self-enclosed robotic devices to surface sample once per day.

article thumbnail

Driving Pharmacy Value Through Robotics and Connected Technology

Omnicell

Implementing an intelligent infrastructure of automation and intelligence, supported by expert services to ensure optimization, is an opportunity for health systems to enhance medication distribution processes, support sterile compounding safety and efficiency, and ultimately improve pharmacy supply chain management.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Reducing Drug Spend with IV Robotic Services

Omnicell

Studies have shown that one out of every ten can put patients at risk. Sterile compounding is also one of the costliest functions in pharmacy operations. Still, many hospital pharmacies continue to struggle to improve safety and efficiency in their sterile compounding operations. 5 at 2 p.m. EDT (11 a.m.

article thumbnail

Autonomous Pharmacy Drives Efficient Hospitals, Safer Patients

Omnicell

By connecting medication inventory across the entire healthcare infrastructure and leveraging the data pulled from that technology, there is a huge opportunity to reduce instances of human error, improve efficiency, control costs, ensure compliance and, ultimately, enhance patient care and safety.

article thumbnail

Driving Value Through Technology-as-a-Service

Omnicell

Overreliance on 503B facilities for sterile compounding led them to seek a solution that would reduce outsourcing costs and waste by better managing supply challenges through improved efficiency. Gee Mathen, Director of Pharmacy Clinical Applications and Technical Services, realized that technology alone wouldn't solve the issue.

article thumbnail

Despite Safety and Supply Challenges, Outsourcing IV Compounding Remains High

Omnicell

Stephanie Gallagher, PharmD, MBA Senior Clinical Product Marketing Manager, Omnicell The sterile compounding industry has been under great scrutiny due to alarming frequency and severity of adverse events from IV compounding, such as the New England Compounding Center catastrophe in 2012.

article thumbnail

Unleash Pharmacy Transformation with Intelligent Infrastructure

Omnicell

BMHCC is simultaneously focused on the challenges of reducing acute care drug spend and improving their drug delivery model, with IV preparation and diversion detection as the chief drug delivery concerns. The goal is to move pharmacists and other clinicians to the center of patient care where they can practice at the top of their license.